The Medical Device Reality That Nobody Talks About
I spent twelve years working on the regulatory and product side of medical technology companies, and what I learned is usually the opposite of what the investor pitch decks suggest. There is a company called Richard Shulman Medical Technologies Group that comes up in conversations about medical device innovation, and the full story involves more than just the glossy press releases. The title Richard Shulman Medical Technologies Group Shocking Facts Revealed Profits Patients And The Hidden Costs Of Innovation keeps appearing in search results because people are trying to understand the gap between how these companies present themselves and what actually happens on the ground. Richard Shulman is a physician and entrepreneur who has been involved with medical device development for decades. The group operates in the space of orthopedic and surgical technology, which is a segment of the market where margins are significant but so are the barriers to entry. What most people do not understand is how the economics actually work once you strip away the venture capital narratives. The innovation pipeline in medical devices is measured in years, not quarters. A typical implant or surgical tool goes through design, prototyping, preclinical testing, clinical trials, regulatory submission, manufacturing scale-up, and then post-market surveillance. That is a five to eight year timeline before the company sees any meaningful revenue. During that entire period, the company is burning cash. Investors get excited about the potential. Surgeons get excited about the tool. But the financial reality is that the hidden costs accumulate in ways that are not obvious from the outside.
I worked with a team that was developing a new surgical instrument, and we had budgeted for regulatory consulting, clinical site management, and manufacturing validation. What we did not adequately budget for was the iterative redesign cycle that happened after the first bench testing. The initial design failed a fatigue test at week four. We had to go back to engineering, retool the manufacturing process, redo the biocompatibility documentation, and resubmit everything to the testing laboratory. That single failure added fourteen months and approximately $600,000 to our development timeline. Nobody in the executive summary mentioned that possibility because it is treated as an outlier event, but in practice it is common enough that any realistic budget needs to account for at least one major redesign cycle. The profit structure of companies in this space is built on a few key mechanisms. Once a device receives regulatory clearance, the company owns the intellectual property around the design. That creates a window of exclusivity, typically two to five years depending on the technology and whether any patent extensions apply. During that window, the company can price the device at a premium because hospitals and surgical centers have already invested in the training and infrastructure to use it. Switching costs are real and expensive. A hospital that has trained its orthopedic surgeons on a particular system will not switch just because a competitor offers a slightly lower price. But the revenue does not come quickly, and the costs do not stop after the product launches. Post-market adverse event reporting, periodic regulatory audits, and ongoing clinical data collection require dedicated staff and ongoing expenditure. I saw a company that had successfully brought a device to market and then struggled to maintain profitability because they underestimated the ongoing compliance burden. They had hired one regulatory affairs person for the entire post-market phase. That was a mistake. The workload required at least three full-time equivalents just to stay current with reporting requirements and audit preparation.
The patient side of this equation is complicated. On one hand, the devices these companies produce enable surgeries that would not otherwise be possible. Minimally invasive orthopedic procedures, for example, reduce recovery time and complication rates compared to traditional open surgery. That is a genuine benefit. On the other hand, the pricing structure means that patients and insurance systems bear the cost of the entire development pipeline, including all the failures that happened along the way. A single successful device has to subsidize the multiple projects that did not make it past clinical trials. That cost gets baked into the price of every implant sold. There is a counter-intuitive aspect to medical device innovation that most people miss. The companies that appear most innovative on paper are not always the ones delivering the most value. What matters more is the execution capability — the ability to navigate regulatory pathways efficiently, manage clinical trial logistics, and scale manufacturing without quality failures. I have seen companies with brilliant designs fail because they could not produce the device at the volume and consistency required by hospital procurement departments. A device that works in a lab but cannot be manufactured reliably at scale is worthless in the marketplace. Another thing that is not discussed often enough is the relationship between device companies and surgical specialists. Key opinion leaders at major medical centers play a disproportionate role in shaping product development. That is by design — companies recruit surgeons to provide input during the development phase. The benefit is that the resulting product is more likely to meet actual clinical needs. The downside is that it creates a dependency on a small group of physicians, and their involvement can influence clinical trial design and data interpretation in ways that are not always transparent. This is normal industry practice, not something unique to any single company, but it is worth understanding when you are evaluating the claims around a new device.
Get the Full Details
The hidden costs also extend to the reimbursement landscape. Getting a device approved by the regulatory body is one thing. Getting it covered by insurance payers is another entirely separate process. Payers evaluate clinical evidence differently than regulators do. They want to see comparative effectiveness data — how does this device perform relative to the existing standard of care? Producing that data requires additional studies that are expensive and time-consuming. Some companies skip this step initially and hope to address it later, but that strategy creates problems when hospitals start requesting the device and payers refuse to cover it. I watched a product launch get quietly stalled because the reimbursement pathway was never clearly established before the commercial rollout began. If you are looking at this from an investment perspective, the key metric to watch is the burn rate relative to the development milestones. A company that is spending aggressively but not hitting regulatory or clinical milestones is burning through capital with no clear path to revenue. Conversely, a company that moves methodically through each phase, even if the timeline is longer, tends to have a more sustainable trajectory. The flashy launches get the attention, but the quiet steady progress is what actually builds a profitable business. From a practical standpoint, the people who understand this space best are the ones who have lived through a full product lifecycle — from initial concept through regulatory approval, market launch, and the ongoing post-market phase. The theoretical knowledge from textbooks and pitch decks does not prepare you for the operational realities. Supply chain disruptions, unexpected clinical site issues, last-minute regulatory feedback, and manufacturing defects are the norm, not the exception. Any plan that does not account for these eventualities is unrealistic.
The medical technology sector will continue to produce new devices and new companies. The economics will remain the same. The costs of innovation are real and substantial, and they are distributed across the entire healthcare system in ways that are not always visible to patients or investors. Understanding that distribution is the difference between seeing the surface narrative and understanding how the industry actually functions.
